114-21-6

Usage

Uses

Used in Pharmaceutical Industry:
DL-Mandelic Acid Sodium Salt is used as an antiseptic for urinary tract infections. It helps in the treatment and prevention of infections by inhibiting the growth of harmful bacteria.
Used in Environmental and Occupational Health:
DL-Mandelic Acid Sodium Salt is used as a short-term exposure biomarker in urine from workers exposed to styrene. It helps in monitoring the level of exposure to harmful chemicals and assessing the potential health risks associated with it.

Purification Methods

It crystallises from 95% EtOH and is dried in a vacuum. [Ross & Morrison J Chem Soc 1019 1933, Banks & Davies J Chem Soc 74 1938, Beilstein 10 III 450.]

InChI:InChI=1/C8H8O3.Na/c9-7(8(10)11)6-4-2-1-3-5-6;/h1-5,7,9H,(H,10,11);/q;+1/p-1

Upstream product

• 611-71-2 MANDELIC ACID 

Downstream Products

• 67315-76-8 α-deutero mandelic acid 
• 1345345-30-3 [Ti(IV)Cl(acetylacetonate)(palmitate)(O₂CCH(OH)C₆H₅)] 
• 1345345-31-4 [Ti(IV)(acetylacetonate)(palmitate)(O₂CCH(OH)C₆H₅)2] 
• 7195-89-3 copper(II) dl-mandelate 
• 7195-93-9 cobalt(II) dimandelate 
• 19944-55-9 nickel(II) dimandelate 
• 67021-74-3 n-Bu₃Sn(Mal) 
• 150296-64-3 trimethyltin α-phenyl-α-oxoacetate 

Relevant academic research and scientific papers

Design, spectral characterization, anti-tumor and anti-inflammatory activity of triorganotin(IV) hydroxycarboxylates, apoptosis inducers: In vitro assessment of induction of apoptosis by enzyme, DNA-fragmentation, acridine orange and comet assays Antitumor Active Organotin Compounds

Interaction of triorganotin(IV) chlorides with sodium salt of hydroxycarboxylic acids results in the formation of triorganotin(IV) hydroxycarboxylates, R3Sn(L) [R = Me, n-Bu and Ph; L = anion of glucuronic (HGlu), gallic (HGal) and mandelic (HMal) acid]. They exhibit trigonal-bipyramidal geometry which is well supported by elemental analysis, IR, 1H, 13C, 119Sn NMR and ESI-MS spectral data. Triorganotin(IV) hydroxycarboxylates have been screened in vitro against five cancer cell lines of human origin viz. MCF-7, HEK-293, PC-3, HCT-15 and HepG-2. Title complexes are found to be cytotoxic to mildly cytotoxic, and exhibited IC50 values in the range 4-30 μg/mL. The results of enzyme assays viz. glutathione reductase, glutathione peroxidase, total glutathione content and lipid peroxidase assay on MCF-7 cells indicate that the reactive oxygen species generated in the cancer cells by triorganotin(IV) hydroxycarboxylates is responsible for cell death. Marginal increase of lactate dehydrogenase suggests that necrosis is also occurring to a small extent. DNA (deoxyribonucleic acid) fragmentation assay, acridine orange assay and comet assay clearly support that the cell death is mainly due to apoptosis. The results obtained for the in vivo anti-inflammatory activity (% inhibition) and toxicity (LD50 in mg/kg) suggested that the complexes have low toxicity and good anti-inflammatory activity.

Process for resolving DL-Mandelic acid with novel 2-benzylamino-1-butanols

A process for resolving DL-Mandelic acid which comprises reacting at moderately elevated temperatures in a two-phase liquid mixture of water and a suitable water-immiscible organic solvent about equimolecular amounts of DL-Mandelic acid and an optically active 2-benzylamino-1-butanol, represented by formula (I), STR1 to form a crude mandelate salt, represented by formula (II), STR2 wherein X is chloro, bromo, fluoro, or nitro; said crude mandelate salt is recovered and purified by contact with a suitable solvent to obtain an optically pure mandelate salt, represented by formula (II); the optically active mandelate salt is hydrolyzed with aqueous sodium or potassium hydroxide in a two-phase liquid mixture to obtain an organic phase containing an optically active compound of formula (I) and an alkalized aqueous phase containing the sodium or potassium salt of an optically active mandelic acid. The latter is acidified and an optically active mandelic acid is recovered therefrom.